Ongoing treatment(s)-Chemotherapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Chemotherapy Posts on Medivizor

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Posted by on Apr 14, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that...

Read More

What is the usefulness of measurable residual disease in patients with acute myeloid leukemia treated with venetoclax and azacitidine?

What is the usefulness of measurable residual disease in patients with acute myeloid leukemia treated with venetoclax and azacitidine?

Posted by on Mar 15, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes for acute myeloid leukemia (AML) patients treated with venetoclax (Venclexta) and azacitidine (Vidaza) who achieved complete remission (CR) and minimal measurable residual disease (MRD) after treatment.  This study concluded that patients who achieved both CR and minimal...

Read More

Evaluating the occurrence and predictors of peripheral nerve disease after breast cancer treatment.

Evaluating the occurrence and predictors of peripheral nerve disease after breast cancer treatment.

Posted by on Oct 3, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the occurrence and clinical predictors of peripheral neuropathy (PN; nerve damage) in long-term survivors of breast cancer (BC). The data showed that PN is an important long-term consequence of taxane-based chemotherapy in survivors of BC. Some background BC is one of the most common forms of cancer in women....

Read More

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Posted by on Aug 29, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...

Read More

Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.

Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.

Posted by on Aug 22, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of nimotuzumab (Theraloc) combined with chemoradiotherapy (CRT) for the treatment of patients with locally advanced squamous non-small cell lung cancer (SqNSCLC). The data showed that nimotuzumab plus CRT had similar survival outcomes compared to CRT alone, but with a lower...

Read More

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL).  This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...

Read More

Can reducing chemotherapy duration from 6 to 3 months reduce side effects in patients with colorectal cancer and still be effective?

Can reducing chemotherapy duration from 6 to 3 months reduce side effects in patients with colorectal cancer and still be effective?

Posted by on Mar 6, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated if reducing therapy duration could reduce side effects in patients but still be effective in patients with stage II colorectal cancer (CRC). This study showed that in certain patients a 3-month treatment duration can be considered.  Some background Patients with colorectal cancer (CRC) can be treated...

Read More

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...

Read More

Can a healthy diet improve quality of life of women with breast cancer undergoing chemotherapy?

Can a healthy diet improve quality of life of women with breast cancer undergoing chemotherapy?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study examined whether a healthy diet can improve the quality of life of women with breast cancer undergoing chemotherapy. The authors found that women who followed healthy dietary advice had an improvement in the quality of their life during chemotherapy, reducing nausea, vomiting, and increasing appetite.  Some background...

Read More

How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?

How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?

Posted by on Feb 26, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome. Some background Rectal cancer is commonly treated with surgery to remove the tumor. LARC is...

Read More

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Posted by on Jan 19, 2021 in Lung cancer | 0 comments

In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP.  Some...

Read More